- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Hairy Cell Leukemia - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
Table of Contents
1
UI - 12057121
AU - Savoie L; Johnston JB
TI -
Hairy cell leukemia.
SO - Curr Treat Options Oncol 2001 Jun;2(3):217-24
AD - CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba, Canada,
R3E0V9.
The standard therapy for hairy cell leukemia (HCL) is with the
nucleoside analogs, 2"-deoxycoformycin (dCF) or 2-chlorodeoxyadenosine
(CdA), which produce morphologic complete remissions (CRs) in the
majority of patients, although residual hairy cells can frequently be
detected by molecular or immunologic techniques. Relapses continue to
occur over time, but most patients respond well to retreatment with the
same agent. The longest follow-up is for patients treated with dCF,
where the 5- and 10-year relapse-free survival rates are 80% to 85% and
67% to 76%, respectively. dCF is usually administered as 4 mg/m2
intravenously every second week until CR followed by two additional
treatments for consolidation. CdA is administered as 0.09 mg/kg/d x 7,
by continuous intravenous infusion, although it may be equally effective
when given as daily boluses or subcutaneously. More recent studies have
suggested that CdA, 0.15 mg/kg intravenously weekly x 6, produces
equivalent response rates, while reducing the risk of febrile
neutropenia (which occurs in approximately 50% of patients using the
standard regimen). We have found this to be a very simple, safe, and
effective regimen. Both dCF and CdA should be used with caution in the
presence of renal or hepatic dysfunction, and both are contraindicated
in the presence of active infection. Interferon-alfa (3 x 10(6) U
subcutaneously three times per week for 12 months) produces inferior
response rates but is less likely to cause febrile neutropenia. It can
be considered for initial treatment for patients with active infection,
patients at high risk of febrile neutropenia, and patients who cannot
tolerate or are resistant to the nucleoside analogs. Splenectomy is now
rarely performed in HCL, but it is required for splenic rupture and may
be of value in "splenic" HCL or those with massive splenomegaly and
hypersplenism. In preliminary studies, monoclonal antibodies directed
against CD20 or CD25 also show activity in HCL, but their roles in this
disease require further study.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
